The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients’ Diagnosis and Prognosis
Gliomas account for approximately 70% of primary brain tumors in adults. Of all gliomas, grade IV astrocytoma, also called glioblastoma, has the poorest overall survival, with <5% of patients surviving five years after diagnosis. Due to the aggressiveness, lethal nature, and impaired surgical acc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Brain Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3425/10/11/872 |
| _version_ | 1797547529081978880 |
|---|---|
| author | Rūta Urbanavičiūtė Kęstutis Skauminas Daina Skiriutė |
| author_facet | Rūta Urbanavičiūtė Kęstutis Skauminas Daina Skiriutė |
| author_sort | Rūta Urbanavičiūtė |
| collection | DOAJ |
| description | Gliomas account for approximately 70% of primary brain tumors in adults. Of all gliomas, grade IV astrocytoma, also called glioblastoma, has the poorest overall survival, with <5% of patients surviving five years after diagnosis. Due to the aggressiveness, lethal nature, and impaired surgical accessibility of the tumor, early diagnosis of the tumor and, in addition, prediction of the patient’s survival time are important. We hypothesize that combining the protein level values of highly recognizable glioblastoma serum biomarkers could help to achieve higher specificity and sensitivity in predicting glioma patient outcome as compared to single markers. The aim of this study was to select the most promising astrocytoma patient overall survival prediction variables from five secretory proteins—glial fibrillary acidic protein (GFAP), matrix metalloproteinase-2 (MMP-2), chitinase 3-like 1 (CHI3L1), osteopontin (OPN), and amphiregulin (AREG)—combining them with routinely used tumor markers to create a Patient Survival Score calculation tool. The study group consisted of 70 astrocytoma patients and 31 healthy controls. We demonstrated that integrating serum CHI3L1 and OPN protein level values and tumor isocitrate dehydrogenase 1 <i>IDH1</i> mutational status into one parameter could predict low-grade astrocytoma patients’ two-year survival with 93.8% accuracy. |
| first_indexed | 2024-03-10T14:45:21Z |
| format | Article |
| id | doaj.art-ec53d427eda343ec9f000ca98560691d |
| institution | Directory Open Access Journal |
| issn | 2076-3425 |
| language | English |
| last_indexed | 2024-03-10T14:45:21Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Brain Sciences |
| spelling | doaj.art-ec53d427eda343ec9f000ca98560691d2023-11-20T21:28:23ZengMDPI AGBrain Sciences2076-34252020-11-01101187210.3390/brainsci10110872The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients’ Diagnosis and PrognosisRūta Urbanavičiūtė0Kęstutis Skauminas1Daina Skiriutė2Laboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str. 4, LT50161 Kaunas, LithuaniaLaboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str. 4, LT50161 Kaunas, LithuaniaLaboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences, Eiveniu str. 4, LT50161 Kaunas, LithuaniaGliomas account for approximately 70% of primary brain tumors in adults. Of all gliomas, grade IV astrocytoma, also called glioblastoma, has the poorest overall survival, with <5% of patients surviving five years after diagnosis. Due to the aggressiveness, lethal nature, and impaired surgical accessibility of the tumor, early diagnosis of the tumor and, in addition, prediction of the patient’s survival time are important. We hypothesize that combining the protein level values of highly recognizable glioblastoma serum biomarkers could help to achieve higher specificity and sensitivity in predicting glioma patient outcome as compared to single markers. The aim of this study was to select the most promising astrocytoma patient overall survival prediction variables from five secretory proteins—glial fibrillary acidic protein (GFAP), matrix metalloproteinase-2 (MMP-2), chitinase 3-like 1 (CHI3L1), osteopontin (OPN), and amphiregulin (AREG)—combining them with routinely used tumor markers to create a Patient Survival Score calculation tool. The study group consisted of 70 astrocytoma patients and 31 healthy controls. We demonstrated that integrating serum CHI3L1 and OPN protein level values and tumor isocitrate dehydrogenase 1 <i>IDH1</i> mutational status into one parameter could predict low-grade astrocytoma patients’ two-year survival with 93.8% accuracy.https://www.mdpi.com/2076-3425/10/11/872cancergliomaglioblastomapatient survival scoreblood serum |
| spellingShingle | Rūta Urbanavičiūtė Kęstutis Skauminas Daina Skiriutė The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients’ Diagnosis and Prognosis Brain Sciences cancer glioma glioblastoma patient survival score blood serum |
| title | The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients’ Diagnosis and Prognosis |
| title_full | The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients’ Diagnosis and Prognosis |
| title_fullStr | The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients’ Diagnosis and Prognosis |
| title_full_unstemmed | The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients’ Diagnosis and Prognosis |
| title_short | The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients’ Diagnosis and Prognosis |
| title_sort | evaluation of areg mmp 2 chi3l1 gfap and opn serum combined value in astrocytic glioma patients diagnosis and prognosis |
| topic | cancer glioma glioblastoma patient survival score blood serum |
| url | https://www.mdpi.com/2076-3425/10/11/872 |
| work_keys_str_mv | AT rutaurbanaviciute theevaluationofaregmmp2chi3l1gfapandopnserumcombinedvalueinastrocyticgliomapatientsdiagnosisandprognosis AT kestutisskauminas theevaluationofaregmmp2chi3l1gfapandopnserumcombinedvalueinastrocyticgliomapatientsdiagnosisandprognosis AT dainaskiriute theevaluationofaregmmp2chi3l1gfapandopnserumcombinedvalueinastrocyticgliomapatientsdiagnosisandprognosis AT rutaurbanaviciute evaluationofaregmmp2chi3l1gfapandopnserumcombinedvalueinastrocyticgliomapatientsdiagnosisandprognosis AT kestutisskauminas evaluationofaregmmp2chi3l1gfapandopnserumcombinedvalueinastrocyticgliomapatientsdiagnosisandprognosis AT dainaskiriute evaluationofaregmmp2chi3l1gfapandopnserumcombinedvalueinastrocyticgliomapatientsdiagnosisandprognosis |